1. Introduction {#sec1}
===============

Cardiovascular disease is one of the major diseases that seriously threaten the health of several people worldwide \[[@B1]\]. Currently, there are several studies that have illustrated the pathological changes of the vascular wall that underlie cardiovascular events and play an important role in the progression of cardiovascular diseases \[[@B2]--[@B4]\]. Furthermore, changes in the structure of arterial wall caused declination in arterial compliance that might precede the clinical symptoms of the disease \[[@B5]--[@B7]\]. Therefore, arterial elasticity and function are used as a variety of cardiovascular risk factors for subclinical vascular lesions \[[@B8]--[@B10]\]. Recently, it has been demonstrated that arterial stiffness is another important risk factor that is independent of other cardiovascular risk factors and is considered to be an alternative endpoint of cardiovascular disease, and is associated with the morbidity and mortality of cardiovascular disease \[[@B11]--[@B13]\].

According to a previous study, angiotensin II is a potent vasoactive peptide in endothelial renin-angiotensin system (RAS), and angiotensin receptor blockers lower blood pressure (BP) and improve arterial elasticity \[[@B14]\]. Therefore, we speculated the beneficial impact of angiotensin-converting enzyme inhibitors (ACEIs) on arterial stiffness that extends beyond BP reduction \[[@B15]\]. Many studies illustrated the potential impact of ACEIs on arterial stiffness in various populations, and reported a protective role of ACEIs against arterial stiffness in hypertensive patients \[[@B16], [@B17]\]. Further, hypertension is characterized by thickened arterial wall, reduced blood vessel elasticity, and lumen dilatation prior to the rise in BP, which involves as vascular remodeling and is also a major cause of hypertensive complications. The structure and function of blood vessels should be restored in hypertensive patients receiving ACEIs, reducing the occurrence of cardiovascular and cerebrovascular events \[[@B18]--[@B21]\].

Arterial stiffness is predominantly reflected by the traveling speed of this pulse wave, and is termed as the pulse wave velocity (PWV) \[[@B22], [@B23]\]. According to the Europe Hypertension Management Guidelines that was published by the Society of Hypertension and the European Society of Cardiology (ESC/ESH) for the first time, PWV is included as one of the limb indicators for assessing subclinical target organ damage in hypertension \[[@B24]\]. Studies have emphasized the importance of applying PWV for representing arterial stiffness \[[@B8], [@B25]--[@B27]\]. Mallareddy et al. evaluated adult hypertensive patients without complex arterial structural or hemodynamic changes administered an ACEI for \>4 weeks, and confirmed that ACEIs have a role in reducing PWV levels \[[@B28]\]. Meanwhile, Kithas and Supiano evaluated patients with essential hypertension otherwise in good general health (no underweight or morbid obesity) after 6 months of treatment, and confirmed the role of hydrochlorothiazide and spironolactone in lowering PWV levels \[[@B29]\]. However, there is a lack of latest meta-analysis results regarding the comparison of the effects of ACEIs versus placebo or other hypertensive agents on PWV (brachial-ankle PWV \[ba-PWV\] and carotid-femoral PWV \[cf-PWV\]) levels. Therefore, this meta-analysis was performed to assess the effectiveness of ACEIs on arterial stiffness.

2. Methods {#sec2}
==========

2.1. Data Sources, Search Strategy, and Selection Criteria {#sec2.1}
----------------------------------------------------------

This review was conducted and reported according to the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement issued in 2009 (Checklist S1) \[[@B30]\]. RCTs published in English and those that investigated the effectiveness of ACEIs on arterial stiffness were systematically searched from PubMed, Embase, and the Cochrane library till September 2018. There were no restrictions placed on publication status (published, in press, or in progress). The main search terms used were as follows: ("ramipril" or "cilazapril" or "quinapril" or "perindopril" or "lisinopril" or "captopril" or "Temocapril" or "quinapril" or "angiotensin-converting enzyme inhibitors" or "ACEI") AND ("pulse wave velocity" or "PWV") and are defined as "humans," and "randomized controlled trials." Furthermore, the references of eligible studies were manually searched for any eligible articles.

The literature search and study selection were undertaken by 2 authors independently by using a standardized approach. Any inconsistencies were settled by a corresponding author. Studies were considered eligible for inclusion if the following criteria were met: (1) studies with RCT design; (2) adult patients regardless of disease status; (3) the intervention was ACEIs and the control group was placebo or other hypertensive agents; and (4) the study should report PWV (ba-PWV and cf-PWV). The exclusion criteria were as follows: animal experiments and duplicated studies; studies designed as cross-over designs; and PWV was not categorized as ba- or cf-PWV.

2.2. Data Collection and Quality Assessment {#sec2.2}
-------------------------------------------

All reliable and interested data of baseline characteristics and primary endpoints in the studies are extracted by two reviewers, respectively. In addition, if more than two arms compared the efficacy of ACEIs vs. other medications, all the relevant data associated with other medications should be pooled and interested endpoints were extracted and used to perform the pooled analysis. The data collected included the following information: first author\'s name, publication year, country, sample size, mean age, percentage male, baseline systolic blood pressure/diastolic blood pressure (SBP/DBP), intervention, control, follow-up duration, baseline PWV, and the PWV and SBP/DBP levels after interventions. The Jadad score was used to evaluate methodological quality of RCTs in this meta-analysis \[[@B31]\]. Briefly, the overall scale of a clinical trial was described from 0 to 5 if using the Jadad scale. In this meta-analysis, individual trials with scores 4 or 5 are regarded as high-quality studies.

2.3. Statistical Analysis {#sec2.3}
-------------------------

Continuous variables were presented as mean and standard deviation, the summary of weighted mean differences (WMDs) and 95% confidence intervals (CIs) were employed to calculate the effect of ACEIs on arterial stiffness, and SBP/DBP was evaluated by using random-effects model \[[@B32], [@B33]\]. The heterogeneity size was determined with *I*^2^ and *Q* statistics, and *P* value of less than 0.10 was considered as significant heterogeneity \[[@B34], [@B35]\]. Sensitivity analysis was conducted for investigating the outcomes to evaluate the impact of single study on overall analysis \[[@B36]\]. Subgroup analyses were conducted for ba-PWV, cf-PWV, SBP, and DBP based on country, mean age, percentage male, follow-up duration, baseline PWV, and study quality after excluding the study that included patients with normal blood pressure (mean SBP\<140 mm Hg). Furthermore, interaction tests were performed to evaluate the differences between subgroups \[[@B37]\]. Funnel plots were drawn, and were used to perform Egger and Begg tests for the included articles for determining the presence of any publication bias \[[@B38], [@B39]\]. The test level for pooled results, sensitivity, subgroup, and publication bias was 0.05. Statistical analyses were performed by using STATA software (version 10.0; Stata Corporation, College Station, TX, USA).

3. Results {#sec3}
==========

3.1. Literature Selection {#sec3.1}
-------------------------

The search results of RCTs by the two reviewers were highly consistent. After utilizing the search strategy, a total of 513 published articles were retrieved. After screening the titles and abstracts according to the inclusion and exclusion criteria, 438 articles were discarded due to irrelevance of topic, animal studies, drug treatment, or improper evaluation of effectiveness and outcomes. Reading the full texts of the remaining 75 studies yielded 17 studies for inclusion, and 58 studies were excluded due to non-RCT or cross-over designs, no desired outcomes (ba-PWV and cf-PWV), or no appropriate control. Finally, 17 studies were selected for final meta-analysis \[[@B40]--[@B56]\]. The results of study-selection process are presented in [Figure 1](#fig1){ref-type="fig"}.

3.2. Characteristics of Included Studies {#sec3.2}
----------------------------------------

The general characteristics of each included study are listed in [Table 1](#tab1){ref-type="table"}. There were 1,458 patients in the included RCTs, and their mean age ranged from 32.8 to 69.0 years. The included studies were conducted in Argentina, Japan, Poland, Malaysia, UK, Italy, Greece, and Spain. Among the included studies, 4 studies reported ba-PWV and 14 studies reported cf-PWV. Fifteen studies included hypertensive patients, and the remaining 2 studies included individuals with normal BP. The duration of intervention ranged from 8--48 weeks. Study quality was evaluated by using the Jadad scale, and 9 studies had a score of 4, and the remaining had a score of 3.

3.3. ba-PWV {#sec3.3}
-----------

Data regarding the effect of ACEIs on ba-PWV were available from 4 studies. The summary results indicated no significant differences between ACEIs and control regarding the change of ba-PWV levels (WMD: −0.35; 95% CI: −2.06 to 1.36; *P*=0.688; [Figure 2(a)](#fig2){ref-type="fig"}), and significant heterogeneity was observed (*P* \< 0.001). Furthermore, no significant differences were observed in hypertensive patients (WMD: 0.31; 95% CI:−0.48 to 1.10; *P*=0.443; substantial heterogeneity), and ACEIs were associated with lower ba-PWV levels in normal subjects (WMD: −2.40; 95% CI: −2.54 to −2.26; *P* \< 0.001). Hence, a sensitivity analysis was conducted, while the conclusion was unaffected by sequential exclusion of any specific study ([Figure 2(b)](#fig2){ref-type="fig"}). Although country, mean age, percentage male, control, baseline PWV, and study quality might affect the treatment effects of ACEIs on ba-PWV levels (*P* \< 0.05), subgroup analyses indicated that the ACEIs were associated with increased levels of ba-PWV if the study was conducted in Western countries (WMD: 1.02; 95% CI: 0.17 to 1.87; *P*=0.019), mean age of \<60.0 years (WMD: 0.71; 95% CI: 0.04 to 1.39; *P*=0.037), percentage male ≥60.0% (WMD: 1.02; 95% CI: 0.17 to 1.87; *P*=0.019), compared with ARB (WMD: 0.71; 95% CI: 0.04 to 1.39; *P*=0.037), baseline PWV of \<10.0 (WMD: 1.02; 95% CI: 0.17 to 1.87; *P*=0.019), and high-quality studies (WMD: 1.02; 95% CI: 0.17 to 1.87; *P*=0.019) ([Table 2](#tab2){ref-type="table"}). The publication bias for ba-PWV was shown in [Figure 2(c)](#fig2){ref-type="fig"}, and the Egger (*P*=0.081) or Begg test (*P*=1.000) results showed no significant publication biases for ba-PWV.

3.4. cf-PWV {#sec3.4}
-----------

Data regarding the effects of ACEIs on cf-PWV were available from 14 studies. There was no significant difference between ACEIs and control for cf-PWV level (WMD: −0.44; 95% CI: −0.96 to 0.09; *P*=0.104; [Figure 3(a)](#fig3){ref-type="fig"}). Heterogeneity was observed in the magnitude of the effect across the trials (*P* \< 0.001). No significant difference was observed in hypertensive patients (WMD: −0.13; 95% CI: −0.54 to 0.27; *P*=0.528; substantial heterogeneity), and ACEI was associated with lower cf-PWV levels in normal individuals (WMD: −2.05; 95% CI: −2.15 to −1.94; *P* \< 0.001; without evidence of heterogeneity). The sensitivity analysis results indicated change in the pooled results after excluding the study conducted by Mackenzie et al., \[[@B51]\] which specifically included elderly patients ([Figure 3(b)](#fig3){ref-type="fig"}). Subgroup analysis indicated that the ACEIs were associated with lower levels of cf-PWV when the percentage male was ≥60.0% (WMD: −0.40; 95% CI: −0.75 to −0.04; *P*=0.031) and studies with high-quality scores (WMD: −0.41; 95% CI: −0.79 to −0.03; *P*=0.032) ([Table 3](#tab3){ref-type="table"}). *P* value for interaction tests indicated that country, mean age, percentage male, control, follow-up duration, baseline PWV, and study quality could bias the therapeutic effects between ACEI and control groups (*P* \< 0.05). There was no significant publication bias for cf-PWV (*P* value for Egger: 0.979; *P* value for Begg: 0.827; [Figure 3(c)](#fig3){ref-type="fig"}).

3.5. SBP and DBP {#sec3.5}
----------------

All the included studies reported SBP and SBP at baseline and after interventions. The summary WMD indicated that patients who received ACEI showed no significant difference in SBP compared with the control group (WMD: −0.70; 95% CI: −2.72 to 1.33; *P*=0.500; [Figure 4(a)](#fig4){ref-type="fig"}). Moreover, significant heterogeneity was observed among the included trials. Furthermore, no significant difference was observed between ACEI and control groups regarding the change of DBP (WMD: 0.26; 95% CI: −1.50 to 2.02; *P*=0.772; [Figure 4(b)](#fig4){ref-type="fig"}), and substantial heterogeneity was detected. Subgroup analyses indicated that ACEI was associated with greater reduction in SBP when the follow-up duration was \>24.0 weeks (WMD: −4.43; 95% CI: −8.61 to −0.25; *P*=0.038), whereas ACEI was associated with higher SBP when the baseline PWV was \<10 (WMD: 3.67; 95% CI: 0.11 to 7.23; *P*=0.043; [Table 4](#tab4){ref-type="table"}). Also, ACEI was associated with greater reduction in DBP when compared with CCB (WMD: −1.74; 95% CI: −3.38 to −0.10; *P*=0.038), whereas the reduction in DBP in patients who received ACEIs was smaller when compared with BRB (WMD: 2.57; 95% CI: 0.39 to 4.74; *P*=0.021), and baseline PWV was \<10 (WMD: 3.30; 95% CI: 1.10 to 5.50; *P*=0.003; [Table 5](#tab5){ref-type="table"}).

4. Discussion {#sec4}
=============

In this meta-analysis, the effects of ACEIs on arterial stiffness based on RCTs and changes of PWV (ba-PWV and cf-PWV) were analyzed. Combined data of ba-PWV and cf-PWV levels served as a reflection of the degree of atherosclerosis in the upper-limb and lower-limb indicators. The results of our study showed no significant differences between ACEIs and control in improving the vascular stiffness, including ba-PWV and cf-PWV. Subgroup analyses indicated that the therapeutic effects of ACEIs on ba-PWV could affect by country, mean age, percentage male, control, baseline PWV, and study quality, while cf-PWV levels might be affected by country, mean age, percentage male, control, follow-up duration, baseline PWV, and study quality. Moreover, BP reduction in patients who received ACEIs and controls showed no significant difference.

Numerous meta-analyses have investigated the impact of ACEIs on arterial stiffness \[[@B17], [@B28], [@B57]\]. Mallareddy et al. \[[@B28]\] performed a meta-analysis to investigate the impact of ACEIs on PWV or augmentation index. The results revealed that reduction in PWV was −1.15 m/s for cf-PWV and −1.9 m/s for ba-PWV for patients who received ACEIs. Furthermore, they pointed out that ACEIs had modest beneficial influence on arterial stiffness, which was partly independent of the changes in BP. \[[@B28]\] Shahin et al. examined the effects of ACEIs on arterial stiffness and wave reflections in patients with hypertension. The results revealed that ACEIs vs. placebo showed significantly reduced levels of PWV, while comparison with other antihypertensive drugs showed no significant differences in PWV levels. Moreover, ACEIs reduced PWV levels in patients with different pathological conditions \[[@B57]\]. Xie et al. conducted a meta-analysis based on 8 RCTs and concluded no significant differences between ACEIs and atenolol on the levels of ba-PWV and cf-PWV. Also, ACEIs were inferior over atenolol in peripheral DBP and heart rate, while the levels of peripheral SBP between ACEIs and atenolol showed no significant difference \[[@B17]\]. However, there are several limitations in the previous meta-analyses studies that should be mentioned: (1) various designs of included studies might affect the therapeutic effects of ACEIs on arterial stiffness; (2) the studies included designs of cross-over trial, and had different washout periods, which in turn could bias the effectiveness of ACEIs; (3) the summary results of PWV were combined, and the type of ba-PWV and cf-PWV was analyzed, respectively; and (4) the therapeutic effects of ACEIs on arterial stiffness in patients with specific characteristics were not illustrated. Therefore, this meta-analysis was conducted based on RCTs to minimize the abovementioned limitations to ensure the confidence of our results.

From the funnel plots of the above two analyses, the study using PWV as detection index was less likely to be biased. Therefore, the conclusions of this study will be able to reflect changes in vascular function. Furthermore, the results of this study showed no significant differences between ACEIs and control for the indexes of arterial stiffness. The possible reason for this could be due to the use of various antihypertensive drugs, and the net therapeutic effects of ACEIs among the included trials varied. Moreover, the summary results and 95% CIs of ba-PWV and cf-PWV were affected by the WMD of individual trial. In addition, the treatment effects of ACEI on arterial stiffness could affect the effect size of BP changes. This study showed no significant differences between ACEIs and control regarding the changes of SBP and DBP, suggesting that the therapeutic effects of ACEIs on arterial stiffness were not biased by the changes of SBP and DBP.

The significant therapeutic effects of ACEIs were observed for ba-PWV when compared with ARB or placebo ([Table 2](#tab2){ref-type="table"}). These results indicated that ARB provided superior effects on ba-PWV than ACEIs. Also, ACEIs showed greater reduction in ba-PWV when compared with placebo ([Table 2](#tab2){ref-type="table"}). In addition, the therapeutic effects of ACEIs on cf-PWV levels were affected by country, mean age, percentage male, control, follow-up duration, baseline PWV, and study quality ([Table 3](#tab3){ref-type="table"}). Firstly, the background therapies and lifestyles were correlated with country and mean age, and were associated with the therapeutic effects of ACEI; secondly, the differences in risk stratification between men and women could affect the levels of arterial stiffness; thirdly, the type of control drugs was correlated with the net therapeutic effects between the intervention and control groups; fourthly, the baseline PWV level was associated with the severity of arterial stiffness; and the study quality was correlated with the evidence level and reliability of summary results. However, the results of subgroup analyses were considered unreliable due to the stability of pooled results and substantial heterogeneity within the subgroups.

Although the study was professionally conducted, there were still a few shortcomings that need to be noted. (1) The purpose of this study was to analyze the curative effects of ACEIs on hypertensive patients by meta-analysis. Some studies did not mention the basis for estimating the sample size or did not fully implement the blinding method, and the study sample size was not large enough, impacting on the test results to a certain extent. (2) There were specific differences in the clinical design, type of drug, dose, follow-up time, etc. The usage of ACEIs varied between the included studies, as well as administration of drugs and the duration of intervention, contributing to the heterogeneity of subgroup analysis of the reported endpoints. In addition, other antihypertensive drugs were used as controls. (3) The relatively small number of included studies when combined with large sample clinical trials and small sample size test may lead to bias.

5. Conclusions {#sec5}
==============

Taken together, although there are some limitations, the strengths and inferences of the overall conclusion are overwhelming. Meta-analysis of RCTs suggested that the role of ACEIs in improving arterial stiffness in hypertensive patients were observed in several subsets. These conclusions may not be applicable to the overall populations, and more evidences are needed to compare the prognosis of patients taking ACEIs with other drugs. Future large-scale studies to verify the results of subgroup analyses in this meta-analysis should be conducted.
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![Flow chart of the study-selection process. Of the 513 hits retrieved in the initial database search, 438 were excluded by reviewing abstracts and titles, leaving 75 trials for assessment. After reviewing the full texts, 58 reports were excluded, and a total of 17 articles were included in this meta-analysis.](CDTP2020-7056184.001){#fig1}

![Effects of ACEIs on ba-PWV. (a) Summary of mean differences; (b) sensitivity analysis; (c) funnel plot for publication bias assessment, by Egger\'s and Begg\'s methods. CI, confidence interval; WMD, weighted mean difference; ACEIs, angiotensin-converting enzyme inhibitors; ba-PWV, brachial-ankle pulse wave velocity.](CDTP2020-7056184.002){#fig2}

![The results of the effect of ACEIs on cf-PWV. (a) Summary of mean differences; (b) sensitivity analysis; (c) funnel plot for publication bias assessment, by Egger\'s and Begg\'s methods. CI, confidence interval; WMD, weighted mean difference; ACEIs, angiotensin converting enzyme inhibitors; cf-PWV, carotid-femoral pulse wave velocity.](CDTP2020-7056184.003){#fig3}

![Effects of ACEIs on SBP (a) and DBP (b). Weighted mean differences are provided as well as 95% confidence intervals (CIs). SBP, systolic blood pressure; DBP, diastolic blood pressure.](CDTP2020-7056184.004){#fig4}

###### 

Baseline characteristics of included studies.

  Studies                                Country          Number of patients   Mean age (years)   Percentage male (%)   Baseline SBP/DBP (mmHg)   Intervention                 Control               Follow-up duration   PWV type            Baseline PWV (m/s)   Jadad scale
  -------------------------------------- ---------------- -------------------- ------------------ --------------------- ------------------------- ---------------------------- --------------------- -------------------- ------------------- -------------------- -------------
  London et al. \[[@B40]\]               France           24                   53.5               58.3                  176.9/98.5                Perindopril                  Nitrendipine          48 weeks             cf-PWV              13.0                 3
  Breithaupt-Grogler et al. \[[@B41]\]   Germany          17                   45.0--67.0         NA                    149.9/98.3                Cilazapril                   Hydrochlorothiazide   12 weeks             cf-PWV              9.2                  3
  Asmar et al. \[[@B42]\]                Australia        406                  18.0--84.0         NA                    162.2/98.7                Indapamide and perindopril   Atenolol              48 weeks             cf-PWV              12.3                 4
  Armentano et al. \[[@B43]\]            Argentina        34                   55.0               64.7                  157.0/95.0                Ramipril                     Atenolol              12 weeks             cf-PWV              11.7                 4
  Komai et al. \[[@B44]\]                Japan            25                   62.1               64.0                  152.0/81.9                Cilazapril                   Atenolol              24 weeks             cf-PWV              9.5                  4
  London et al. \[[@B45]\]               Australia        469                  54.9               67.4                  162.3/98.6                Indapamide and perindopril   Atenolol              48 weeks             cf-PWV              12.7                 4
  Anan et al. \[[@B46]\]                 Japan            21                   59.0               47.6                  156.5/97.0                Perindopril                  Valsartan             40 weeks             ba-PWV              18.3                 3
  Ahimastos et al. \[[@B47]\]            Australia        17                   32.8               76.5                  120.4/72.2                Perindopril                  Placebo               24 weeks             cf-PWV and ba-PWV   7.4                  4
  Rehman et al. \[[@B48]\]               Malaysia         39                   52.8               NA                    151.5/93.0                Perindopril                  Losartan              24 weeks             cf-PWV              11.5                 3
  Morimoto et al. \[[@B49]\]             Japan            32                   64.0               46.9                  145.5/82.0                Perindopril                  Amlodipine            24 weeks             ba-PWV              16.4                 3
  Ahimastos et al. \[[@B50]\]            Australia        40                   66.0               95.0                  139.5/87.0                Ramipril                     Placebo               24 weeks             cf-PWV              9.7                  4
  Mackenzie et al. \[[@B51]\]            United Kingdom   32                   69.0               50.0                  159.4/84.1                Perindopril                  Atenolol              10 weeks             cf-PWV              9.3                  3
  Kostka-Jeziorny et al. \[[@B52]\]      Poland           66                   46.2               60.6                  158.2/96.8                Perindopril                  Hydrochlorothiazide   8 weeks              cf-PWV              11.2                 3
  Virdis et al. \[[@B53]\]               Italy            50                   45.0               70.0                  148.4/92.8                Ramipril                     Aliskiren             12 weeks             cf-PWV              7.6                  4
  Koumaras et al. \[[@B54]\]             Greece           37                   48.0               78.4                  148.4/99.4                Quinapril                    Atenolol              10 weeks             cf-PWV              8.8                  3
  Redon et al. \[[@B55]\]                Spain            88                   58.4               60.2                  157.5/96.5                Perindopril                  Olmesartan            24 weeks             ba-PWV              9.2                  4
  Jekell et al. \[[@B56]\]               Sweden           61                   53.6               65.6                  152.5/92.9                Ramipril                     Doxazosin             12 weeks             cf-PWV              8.7                  4

PWV, pulse wave velocity; ba-PWV, brachial-ankle pulse wave velocity; cf-PWV, carotid-femoral pulse wave velocity; SBP, systolic blood pressure; DBP, diastolic blood pressure; NA, not available.

###### 

Subgroup analyses for ba-PWV.

  Group                 WMD and 95% CI          *P* value   Heterogeneity (%)   *P* value for heterogeneity   *P* value for interaction test
  --------------------- ----------------------- ----------- ------------------- ----------------------------- --------------------------------
  Country                                                                                                      
   Eastern              −0.13 (−0.53 to 0.27)   0.527       6.1                 0.302                         0.014
   Western              1.02 (0.17 to 1.87)     0.019       ---                 ---                            
                                                                                                              
  Mean age (years)                                                                                             
   ≥60.0                −0.22 (−0.62 to 0.18)   0.275       ---                 ---                           0.014
   \<60.0               0.71 (0.04 to 1.39)     0.037       9.3                 0.294                          
                                                                                                              
  Percentage male (%)                                                                                          
   ≥60.0                1.02 (0.17 to 1.87)     0.019       ---                 ---                           0.014
   \<60.0               −0.13 (−0.53 to 0.27)   0.527       6.1                 0.302                          
                                                                                                              
  Control                                                                                                      
   ARB                  0.71 (0.04 to 1.39)     0.037       9.3                 0.294                         \<0.001
   CCB                  −0.22 (−0.62 to 0.18)   0.275       ---                 ---                            
                                                                                                              
  Follow-up duration                                                                                           
   \>24                 0.33 (−0.64 to 1.30)    0.504       ---                 ---                           0.530
   ≤24                  0.34 (−0.87 to 1.55)    0.581       85.1                0.010                          
                                                                                                              
  Baseline PWV                                                                                                 
   ≥10.0                −0.13 (−0.53 to 0.27)   0.527       6.1                 0.302                         0.014
   \<10.0               1.02 (0.17 to 1.87)     0.019       ---                 ---                            
                                                                                                              
  Study quality                                                                                                
   High                 1.02 (0.17 to 1.87)     0.019       ---                 ---                           0.014
   Low                  −0.13 (−0.53 to 0.27)   0.527       6.1                 0.302                          

PWV, pulse wave velocity; ba-PWV, brachial-ankle pulse wave velocity; CCB, calcium channel blocker; CI, confidence interval; ARB, angiotensin receptor blocker or inhibitor; DBP, diastolic blood pressure; WMD, weighted mean difference.

###### 

Subgroup analyses for cf-PWV.

  Group                 WMD and 95% CI           *P* value   Heterogeneity (%)   *P* value for heterogeneity   *P* value for interaction test
  --------------------- ------------------------ ----------- ------------------- ----------------------------- --------------------------------
  Country                                                                                                       
   Eastern              −0.46 (−1.78 to 0.86)    0.496       90.1                0.001                         0.042
   Western              −0.06 (−0.54 to 0.42)    0.814       92.5                \<0.001                        
                                                                                                               
  Mean age (years)                                                                                              
   ≥60.0                0.03 (−2.17 to 2.22)     0.979       98.7                \<0.001                       \<0.001
   \<60.0               −0.18 (−0.53 to 0.17)    0.312       69.5                0.002                          
                                                                                                               
  Percentage male (%)                                                                                           
   ≥60.0                −0.40 (−0.75 to −0.04)   0.031       77.5                \<0.001                       \<0.001
   \<60.0               0.45 (−1.00 to 1.89)     0.547       92.2                \<0.001                        
                                                                                                               
  Control                                                                                                       
   ARB                  0.01 (−0.31 to 0.33)     0.961       0.0                 0.642                         0.003
   CCB                  −0.33 (−1.06 to 0.40)    0.373       ---                 ---                            
   Diuretic             −0.07 (−1.15 to 1.01)    0.896       81.0                0.022                          
   BRB                  −0.18 (−0.85 to 0.48)    0.588       95.6                \<0.001                        
                                                                                                               
  Follow-up duration                                                                                            
   \>24                 −0.25 (−0.83 to 0.33)    0.399       87.4                \<0.001                       \<0.001
   ≤24                  −0.10 (−0.72 to 0.53)    0.764       90.8                \<0.001                        
                                                                                                               
  Baseline PWV                                                                                                  
   ≥10.0                −0.12 (−0.59 to 0.35)    0.615       82.7                \<0.001                       \<0.001
   \<10.0               −0.15 (−0.97 to 0.67)    0.719       93.9                \<0.001                        
                                                                                                               
  Study quality                                                                                                 
   High                 −0.41 (−0.79 to −0.03)   0.032       84.9                \<0.001                       \<0.001
   Low                  0.17 (−0.50 to 0.85)     0.615       84.7                \<0.001                        

PWV, pulse wave velocity; cf-PWV, carotid-femoral pulse wave velocity; CCB, calcium channel blocker; CI, confidence interval; ARB, angiotensin receptor blocker or inhibitor; DBP, diastolic blood pressure; WMD, weighted mean difference.

###### 

Subgroup analyses for SBP.

  Group                 WMD and 95% CI           *P* value   Heterogeneity (%)   *P* value for heterogeneity   *P* value for interaction test
  --------------------- ------------------------ ----------- ------------------- ----------------------------- --------------------------------
  Country                                                                                                       
   Eastern              −0.05 (−5.50 to 5.40)    0.985       88.7                \<0.001                       \<0.001
   Western              0.98 (−3.47 to 5.42)     0.667       94.6                \<0.001                        
                                                                                                               
  Mean age (years)                                                                                              
   ≥60.0                1.03 (−3.71 to 5.76)     0.671       92.1                \<0.001                       \<0.001
   \<60.0               0.09 (−4.72 to 4.89)     0.972       90.6                \<0.001                        
                                                                                                               
  Percentage male (%)                                                                                           
   ≥60.0                1.19 (−5.17 to 7.56)     0.713       96.6                \<0.001                       \<0.001
   \<60.0               −0.55 (−3.16 to 2.06)    0.678       54.2                0.088                          
                                                                                                               
  Control                                                                                                       
   ARB                  −0.09 (−4.90 to 4.73)    0.972       66.2                0.019                         \<0.001
   CCB                  −1.57 (−5.61 to 2.47)    0.446       52.1                0.149                          
   Diuretic             5.81 (−10.01 to 21.62)   0.472       92.8                \<0.001                        
   BRB                  0.41 (−5.98 to 6.80)     0.900       97.6                \<0.001                        
                                                                                                               
  Follow-up duration                                                                                            
   \>24                 −4.43 (−8.61 to −0.25)   0.038       85.0                \<0.001                       \<0.001
   ≤24                  2.25 (−0.90 to 5.40)     0.162       82.7                \<0.001                        
                                                                                                               
  Baseline PWV                                                                                                  
   ≥10.0                −2.75 (−6.19 to 0.70)    0.118       88\.                \<0.001                       \<0.001
   \<10.0               3.67 (0.11 to 7.23)      0.043       79.2                \<0.001                        
                                                                                                               
  Study quality                                                                                                 
   High                 −0.14 (−6.27 to 6.00)    0.965       96.9                \<0.001                       \<0.001
   Low                  1.24 (−2.06 to 4.54)     0.461       75.4                \<0.001                        

ARB, angiotensin receptor blocker or inhibitor; CCB, calcium channel blocker; CI, confidence interval; PWV, pulse wave velocity; SBP, systolic blood pressure; WMD, weighted mean difference.

###### 

Subgroup analyses for DBP.

  Group                 WMD and 95% CI           *P* value   Heterogeneity (%)   *P* value for heterogeneity   *P* value for interaction test
  --------------------- ------------------------ ----------- ------------------- ----------------------------- --------------------------------
  Country                                                                                                       
   Eastern              1.18 (−3.54 to 5.90)     0.624       82.7                0.001                         0.910
   Western              1.19 (−0.33 to 2.71)     0.125       78.0                \<0.001                        
                                                                                                               
  Mean age (years)                                                                                              
   ≥60.0                2.70 (−1.98 to 7.39)     0.258       91.4                \<0.001                       0.004
   \<60.0               0.24 (−1.21 to 1.69)     0.744       46.1                0.054                          
                                                                                                               
  Percentage male (%)                                                                                           
   ≥60.0                1.69 (−0.80 to 4.19)     0.184       76.7                \<0.001                       0.162
   \<60.0               −0.00 (−2.96 to 2.95)    0.998       81.8                0.001                          
                                                                                                               
  Control                                                                                                       
   ARB                  0.25 (−2.15 to 2.65)     0.839       26.8                0.243                         0.026
   CCB                  −1.74 (−3.38 to -0.10)   0.038       0.0                 0.685                          
   Diuretic             1.50 (−7.58 to 10.58)    0.746       70.9                0.001                          
   BRB                  2.57 (0.39 to 4.74)      0.021       86.4                \<0.001                        
                                                                                                               
  Follow-up duration                                                                                            
   \>24                 −0.20 (−0.42 to 0.02)    0.074       0.0                 0.870                         \<0.001
   ≤24                  1.89 (-0.34 to 4.12)     0.096       77.7                \<0.001                        
                                                                                                               
  Baseline PWV                                                                                                  
   ≥10.0                −0.58 (−1.55 to 0.40)    0.249       34.2                0.155                         \<0.001
   \<10.0               3.30 (1.10 to 5.50)      0.003       62.9                0.013                          
                                                                                                               
  Study quality                                                                                                 
   High                 1.51 (−0.53 to 3.55)     0.146       76.2                \<0.001                       0.020
   Low                  0.75 (−1.60 to 3.11)     0.530       78.2                \<0.001                        

ARB, angiotensin receptor blocker or inhibitor; CCB, calcium channel blocker; CI, confidence interval; PWV, pulse wave velocity; DBP, diastolic blood pressure; WMD, weighted mean difference.

[^1]: Academic Editor: Kailash Prasad
